NanosonicsNNCSF 90 EV-to-EBIT is 36.39 as of Jul. 13, 2026, which is 68% below its 10-year median of 114.51. GuruFocus rates NNCSF with a GF Score™ of 90/100 and a GF Value™ of $3.51 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 467 Medical Devices & Instruments companies, Nanosonics ranks worse than 75.16% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Nanosonics's Enterprise Value for the quarter that ended in Dec. 2025 was $777.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nanosonics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $15.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanosonics EV-to-EBIT Related Terms
Nanosonics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Nanosonics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Nanosonics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanosonics EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nanosonics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Nanosonics's EV-to-EBIT falls into.
Nanosonics's current Enterprise Value is $562.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nanosonics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $15.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanosonics (NNCSF) has a EV-to-EBIT of 36.39 as of Jul. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Nanosonics and its competitors. This is 68% below median its historical median of 114.51. Over the past decade, Nanosonics' EV-to-EBIT has ranged from 32.04 to 1,292.86. According to the industry distribution chart, Nanosonics ranks #351 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 75.2%.
Is Nanosonics' EV-to-EBIT too high?
Nanosonics' current EV-to-EBIT of 36.39 is 68% below median its 10-year median of 114.51. Over the past 10 years, this metric has ranged from a low of 32.04 to a high of 1,292.86. The Medical Devices & Instruments industry median EV-to-EBIT is 18.49. Nanosonics' value of 36.39 is 96.8% above this industry median. Based on the distribution chart, Nanosonics ranks #351 out of 467 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Nanosonics has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanosonics' EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nanosonics ranks #351 out of 467 companies for EV-to-EBIT. This places Nanosonics in the lower half of its industry. The industry median EV-to-EBIT is 18.49. Nanosonics' value of 36.39 is 96.8% above this benchmark. Historically, Nanosonics' own EV-to-EBIT has ranged from 32.04 to 1,292.86 over the past decade. While the company's 10-year median is 114.51 vs. the industry median of 18.49, Nanosonics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.49, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanosonics's current EV-to-EBIT of 36.39 is 96.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Nanosonics and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanosonics's current EV-to-EBIT is 36.39, which is 68% below median its own 10-year median of 114.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanosonics stock overvalued right now?
Based on GuruFocus' analysis, Nanosonics (NNCSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.51, compared to a current price of $2.55 — trading 27.4% below its estimated fair value. The current EV-to-EBIT is 36.39, which is 68% below median its 10-year median of 114.51 and 96.8% above the Medical Devices & Instruments industry median of 18.49. Nanosonics' overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Nanosonics (NNCSF), the current EV-to-EBIT is 36.39 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanosonics (NNCSF) Overvalued in 2026?
Based on GuruFocus' analysis, Nanosonics stock appears to be undervalued.
The current stock price of $2.55 is trading 27.4% below its estimated GF Value™ of $3.51.
GuruFocus considers Nanosonics to be Modestly Undervalued.
Key valuation signals for NNCSF:
EV-to-EBIT: 36.39 (68% below median its 10-year median of 114.51)
GF Value™: $3.51 vs. price of $2.55 (27.4% below fair value)
Industry Position: 96.8% above the Medical Devices & Instruments median (#351 of 467)
No single metric tells the full story. See the NNCSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanosonics is largely a single-product firm, and its Trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low-temperature sonically activated hydrogen peroxide mist suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection of patients. Nanosonics' revenue consists of capital sales of Trophon units, ongoing consumables sales, and service revenue. By December 2025, there were 38,000 Trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, over 50% in the US to single-digit penetration in Europe, Middle East, and Africa, and elsewhere in the Asia-Pacific region.
90GF Score
Get the complete analysis for NNCSF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNCSF has been successfully added to your 
